NBL-020

N/A

Report date: 2023/02/14 14:10:10

Base Information

Drug NameNBL-020
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 1B antagonists
TargetsTumor necrosis factor receptor superfamily member 1B
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Xinshi Biological Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNovarock Biotherapeutics LtdShanghai Xinshi Biological Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A